Cantor Fitzgerald Estimates Vaxcyte FY2025 Earnings

Vaxcyte, Inc. (NASDAQ:PCVX) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Vaxcyte in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen expects that the company will post earnings per share of ($7.02) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Vaxcyte’s current full-year earnings is ($4.14) per share.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the previous year, the company earned ($0.91) earnings per share.

A number of other research firms also recently issued reports on PCVX. Needham & Company LLC reissued a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, November 6th. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research report on Friday, December 20th. They set a “buy” rating and a $135.00 target price for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $145.71.

Vaxcyte Stock Down 0.4 %

PCVX stock opened at $89.64 on Thursday. The company has a market cap of $11.17 billion, a price-to-earnings ratio of -19.49 and a beta of 0.98. The business has a fifty day simple moving average of $87.24 and a 200-day simple moving average of $93.85. Vaxcyte has a 52 week low of $58.10 and a 52 week high of $121.06.

Hedge Funds Weigh In On Vaxcyte

Institutional investors have recently made changes to their positions in the business. abrdn plc increased its stake in shares of Vaxcyte by 171.4% in the fourth quarter. abrdn plc now owns 224,824 shares of the company’s stock worth $18,404,000 after buying an additional 141,994 shares during the last quarter. Jennison Associates LLC increased its position in shares of Vaxcyte by 0.7% in the 4th quarter. Jennison Associates LLC now owns 1,246,551 shares of the company’s stock worth $102,043,000 after purchasing an additional 9,121 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Vaxcyte by 23.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company’s stock valued at $2,163,000 after purchasing an additional 4,962 shares in the last quarter. Chicago Partners Investment Group LLC lifted its position in shares of Vaxcyte by 9.2% during the fourth quarter. Chicago Partners Investment Group LLC now owns 5,431 shares of the company’s stock worth $440,000 after purchasing an additional 458 shares during the last quarter. Finally, KBC Group NV grew its stake in Vaxcyte by 78.0% in the fourth quarter. KBC Group NV now owns 4,775 shares of the company’s stock worth $391,000 after purchasing an additional 2,092 shares in the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the sale, the director now directly owns 7,175 shares of the company’s stock, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Grant Pickering sold 15,000 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $106.82, for a total value of $1,602,300.00. Following the completion of the transaction, the chief executive officer now directly owns 435,219 shares of the company’s stock, valued at $46,490,093.58. This represents a 3.33 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 85,982 shares of company stock worth $8,108,425 over the last 90 days. Company insiders own 3.10% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.